Literature DB >> 1690130

Recombinant C5a enhances interleukin 1 and tumor necrosis factor release by lipopolysaccharide-stimulated monocytes and macrophages.

J M Cavaillon1, C Fitting, N Haeffner-Cavaillon.   

Abstract

Lipopolysaccharide (LPS) is a potent inducer of interleukin 1 (IL 1) synthesis and release, and of tumor necrosis factor (TNF) secretion. Many signals can enhance the LPS-induced production of these cytokines. We have previously observed that addition of low amounts of normal human serum to the culture medium enhances IL 1 production. Among serum factors, anaphylatoxins C3a and C5a and/or their desArg derivatives have been shown to enhance LPS-induced IL 1 and TNF production. However, the capacity of natural anaphylatoxins to induce by themselves the production of cytokines remains a controversial issue. We have investigated the capacity of human recombinant C5a (hrC5a) to induce IL 1 and TNF production. Despite its lack of direct triggering, hrC5a was able to act synergistically with LPS, leading to higher IL 1 and TNF release by human monocytes and mouse peritoneal macrophages. As assessed by the comitogenic assay, hrC5a increased IL 1 release, whereas cell-associated IL 1 activity was not significantly modified. Measurement by enzyme-linked immunosorbent assay of human IL 1 beta led to similar conclusions, whereas measurement of IL 1 alpha by radioimmunoassay indicated, in addition, an increase in intracellular IL 1 alpha.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1690130     DOI: 10.1002/eji.1830200204

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  37 in total

1.  The C5a receptor is expressed in normal renal proximal tubular but not in normal pulmonary or hepatic epithelial cells.

Authors:  A Fayyazi; O Scheel; T Werfel; S Schweyer; M Oppermann; O Götze; H J Radzun; J Zwirner
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

2.  Superior biocompatibility of heparin-bonded circuits in pediatric cardiopulmonary bypass.

Authors:  T Ozawa; K Yoshihara; N Koyama; S Yamazaki; Y Takanashi
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1999-12

3.  Alterations in mononuclear cell tumour necrosis factor-alpha (TNF-alpha) response in patients on long term cuprophane haemodialysis.

Authors:  A Y Annenkov; A G Strokov; F S Baranova
Journal:  Clin Exp Immunol       Date:  1992-10       Impact factor: 4.330

4.  C5a-induced gene expression in human umbilical vein endothelial cells.

Authors:  Eric A Albrecht; Arul M Chinnaiyan; Sooryanarayana Varambally; Chandan Kumar-Sinha; Terrence R Barrette; J Vidya Sarma; Peter A Ward
Journal:  Am J Pathol       Date:  2004-03       Impact factor: 4.307

Review 5.  Immunobiology of Inherited Muscular Dystrophies.

Authors:  James G Tidball; Steven S Welc; Michelle Wehling-Henricks
Journal:  Compr Physiol       Date:  2018-09-14       Impact factor: 9.090

6.  Chronological changes in the complement system in sepsis.

Authors:  H Nakae; S Endo; K Inada; M Yoshida
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

7.  Pravastatin prevents miscarriages in mice: role of tissue factor in placental and fetal injury.

Authors:  Patricia Redecha; Nico van Rooijen; Donald Torry; Guillermina Girardi
Journal:  Blood       Date:  2009-02-20       Impact factor: 22.113

8.  Systemic and local anti-C5 therapy reduces the disease severity in experimental autoimmune uveoretinitis.

Authors:  D A Copland; K Hussain; S Baalasubramanian; T R Hughes; B P Morgan; H Xu; A D Dick; L B Nicholson
Journal:  Clin Exp Immunol       Date:  2009-12-04       Impact factor: 4.330

9.  Muramyldipeptide and granulocyte-macrophage colony-stimulating factor enhance interferon-gamma-induced nitric oxide production by rat alveolar macrophages.

Authors:  P G Jorens; F J van Overveld; H Bult; P A Vermeire; A G Herman
Journal:  Agents Actions       Date:  1993-01

10.  Pre-neutralization of C5a-mediated effects by the monoclonal antibody 137-26 reacting with the C5a moiety of native C5 without preventing C5 cleavage.

Authors:  M Fung; M Lu; H Fure; W Sun; C Sun; N Y Shi; Y Dou; J Su; X Swanson; T E Mollnes
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.